Considering the scorn heaped on the Jupiter Trial investigators for stopping their trial early ( ask DRRC and STS ) its very unlikely IMHO that RI will be stopped before Interim no matter what the CEO says
And remember ...we are "not unaware " that you are predicting a Nov 15 stop for RI :) Kiwi
I agree as well that JT sounded much more confident than he has in the past. In a prior presentation he made the comment about getting through Reduce-It without diluting. Obviously, the sooner the trial ends the more money they will save and the sooner they can get on with making bigger money from Vascepa. Maybe I am reading too much into this but I believe that once they have study results [assuming they are outstanding and are announced from interim look] they will begin taking offers for the company. No way could AMRN afford the marketing and distribution costs to get Vascepa to over a million people on their own.